MEI Pharma, Inc. (MEIP)

[value1008]

There was a good summation of highlights from MEIP's CEO presentation at Cowen Conference, by a poster at one of the recent articles on MEIP at S.Alpha (in comment-thread to the article by Scott Matusow):

shinobirastafari -- Nice AML data from the Cowen Healthcare Conference today: http://bit.ly/1FaAHOQ

Let's get the good AML data out there from today's presentation:
* 2 new responders since ASH 2014.
* 52% (17/33) have now achieved primary endpoint.
* CR = 33% (11/33) to date.
* No patient who achieved a clinical response has progressed [i.e., worsened in their AML condition].
* Majority of clinical responses occur within the 1st two cycles.
Plus:
* Estimate ~30,000 target pracinostat patients in 7 key markets by 2021
(takes into account high risk MDS / AML patients who respond well to HMAs)
* Debt-free and enough cash ($78.7M) to last until 2016
* 4 data events between now and June

4 Mar, 03:04 PM